Chen, Xun http://orcid.org/0000-0001-6871-2758
Gentili, Matteo http://orcid.org/0000-0002-6970-8133
Hacohen, Nir
Regev, Aviv http://orcid.org/0000-0003-3293-3158
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (5RM1HG006193)
HHMI; Klarman Cell Observatory and Klarman Incubator at the Broad Institute
Article History
Received: 22 October 2020
Accepted: 1 September 2021
First Online: 17 September 2021
Competing interests
: A.R. is a founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas Therapeutics and until August 31, 2020 was an SAB member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov and ThermoFisher Scientific. From August 1, 2020, A.R. is an employee of Genentech. N.H is an equity holder of BioNtech and is an advisor for Related Sciences. X.C. and A.R. are named co-inventors on a patent application (U.S. 63/221,663) related to CeVICA filed by the Broad Institute that is being made available in accordance with COVID-19 technology licensing framework to maximize access to university innovations. M.G. declares no competing interests.